Efficacy of leflunomide 100 mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial;Eficacia de leflunomida 100mg semanales comparado con dosis bajas de metotrexate en pacientes con artritis reumatoide activa. Estudio clínico doble ciego aleatorizado

Reumatologia Clinica

Volumn 8, Issue 5, 2012, Pages 243-249

  Jaimes Hernández, Jorge ^a   Meléndez Mercado, Claudia Irene ^a   Mendoza Fuentes, Angélica ^a   Aranda Pereira, Pablo ^a   Castañeda Hernández, Gilberto ^b  

^a Secretaria de Finanzas del Distrito Federal   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Adverse events in leflunomide; Leflunomide; Monotherapy; Treatment of rheumatoid artritis

Indexed keywords

LEFLUNOMIDE; METHOTREXATE; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADULT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ERUPTION; FEMALE; IMMUNOCOMPROMISED PATIENT; INFECTION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TOXIC HEPATITIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ERUPTIONS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFECTION; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865780053     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2012.03.013     Document Type: Article

References (19)

1. Scott D.L., Smolen J.S., Kalden J.R., Van de Putte L.B.A., Larsen A., Kvien T.K., et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001, 60:913-923.
2. Cohen S., Cannon G.W., Schiff M., Weaver A., Fox R., Olsen N., et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001, 44:1984-1992.
3. Kalden J.R., Scott D.L., Smolen J.S., Schattenkirchner M., Rozman B., Williams B.D., et al. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. J Rheumatology 2001, 28:1983-1991.
4. Jaimes-Hernández J., Robles-San Román M., Suárez-Otero R., Davalos-Zugasti M.E., Arroyo-Borrego S. Rheumatoid arthritis treatment with weekly leflunomide: an open label study. J Rheumatology 2004, 31:235-237.
5. Arnett F.C., Edworthy S.M., Bloch D.A., Mcshane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-334.
6. Abello-Banfi M., Cardiel M.H., Ruíz-Mercado R., Alarcón-Segovia D. Validation of HAQ-Di for Spanish population. Clin Exp Rheumatol 1993, 11:117-121.
7. Felson D., Anderson J., Boers M., Bombardier C., Furst D., Goldsmith C., et al. ACR Preliminary Definition of Improvement in Rheumatoid Arthritis. Arthritis Rheum 1995, 38:727-735.
8. van Gestel A.M., Anderson J.J., Van Riel P.L., Boers M., Haagsma C.J., Rich B., et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology, European League of Associations for Rheumatology. J Rheumatol 1999, 26:705-711.
9. Kremer J.M. Rheumatological creativity and leflunomide [comment]. J Rheumatology 2004, 31:203-204.
10. Van Roon E.N., Jansen T.L., Van de Laar M.A., Janssen M., Yska J.P., Keuper R., et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:569-574.
11. Strand V., Cohen S., Schiff M., Weaver A., Fleischmann R., Cannon G., et al. Treatment of active Rheumatoid Arthritis with Leflunomide compared with Placebo and Methotrexate. Arch Intern Med 1999, 159:2542-2550.
12. Poór G., Strand V. Efficacy and safety of leflunomide 10mg versus 20mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial. Rheumatology (Oxford) 2004, 43:744-749.
13. Maddison P., Kiely P., Kirkham B., Lawson T., Moots R., Proudfoot D., et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford) 2005, 44:280-286.
14. Jakez-Ocampo J., Richaud-Patin Y., Simon J.A., Llorente L. Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study. Joint Bone Spine 2002, 69:307-311.
15. Jakez-Ocampo J., Granados J., Richaud-Patin Y., Sanchez-Guerrero J., Llorente L. Weekly leflunomide as monotherapy for recent-onset rheumatoid arthritis. [Letter]. Arthritis Rheum 2004, 51:147-148.
16. Visser K., Katchamart W., Loza E., Martinez-Lopez J.A., Salliot C., Trudeau J., et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009, 68:1086-1093.
17. Van Roon E.N., Jansen T.L., Houtman N.M., Spoelstra P., Brouwers J.R. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Safety 2004, 27:345-352.
18. Wluca A., Buchbinder R., Mylvaganam A., Hall S., Harkness A., Lewis D., et al. Long term methotrexate use in rheumatoid arthritis. 12 years follw up of 460 patientns treated i community practice. J Rheumatol 2000, 27:1864-1871.
19. Singer O., Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011. Curr Opin Rheumatol 2011, 23:288-292.